[1]王集红,郭永明,刘歆,等.布地奈德混悬液雾化吸入在慢性阻塞性肺疾病急性加重期患者中的应用[J].福建医药杂志,2023,45(02):12-15.
 WANG Jihong,GUO Yongming,LIU Xin,et al.Application of aerosol inhalation of budesonide suspension in acute exacerbation of chronic obstructive pulmonary disease[J].FUJIAN MEDICAL JOURNAL,2023,45(02):12-15.
点击复制

布地奈德混悬液雾化吸入在慢性阻塞性肺疾病急性加重期患者中的应用()
分享到:

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
45
期数:
2023年02期
页码:
12-15
栏目:
临床研究
出版日期:
2023-04-15

文章信息/Info

Title:
Application of aerosol inhalation of budesonide suspension in acute exacerbation of chronic obstructive pulmonary disease
文章编号:
1002-2600(2023)02-0012-04
作者:
王集红郭永明刘歆江发英张春辉张美泉陆君琴
福建医科大学教学医院 福建省老年医院呼吸与危重症医学科(福州 350009)
Author(s):
WANG Jihong GUO Yongming LIU Xin JIANG Faying ZHANG Chunhui ZHANG Meiquan LU Junqin
Department of Respiratory and Critical Care Medicine, Fujian Provincial Geriatric Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350009, China
关键词:
慢性阻塞性肺疾病急性加重期布地奈德不同剂量雾化吸入
Keywords:
AECOPD budesonide different doses atomized inhalation
分类号:
R563.1
文献标志码:
B
摘要:
目的 探讨不同剂量布地奈德雾化吸入治疗慢性阻塞性肺疾病急性加重期(AECOPD)患者的临床疗效。方法 选取我院2020年6月至2021年12月收治的150例AECOPD患者,采用随机数表法分为高剂量组和低剂量组各75例,高剂量组和低剂量组分别按6 mg/d剂量和3 mg/d剂量布地奈德雾化吸入,对比用药前后两组CAT评分、肺功能、血气指标、总有效率及不良反应率的差别。结果 用药后,高剂量组CAT评分为8.09分,低于低剂量组的9.71分(P<0.05);高剂量组肺功能指标FEV1为1.80 L、FEV1/FVC为66.32%、FEV1%预计值为62.77,均高于低剂量组的1.64 L、58.43%、57.99(均P<0.05);高剂量组血气指标PO2为82.45 mm Hg,高于低剂量组的73.62 mm Hg(P<0.05);PCO2为58.03 mm Hg,低于低剂量组的63.95 mm Hg(P<0.05);高剂量组总有效率96.00%,高于低剂量组81.33%(P<0.05);高剂量组不良反应发生率(30.67%)与低剂量组(28.00%)比较的差异无统计学意义(P>0.05)。结论 高剂量布地奈德雾化吸入更有效改善 AECOPD 患者肺功能及缺氧状态,疗效更显著,不良反应率增加不明显。
Abstract:
Objective To investigate the clinical effect of budesonide atomized inhalation suspension with different doses in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods A total of 150 patients with AECOPD diagnosed and treated in our hospital from June 2020 to December 2021 were randomly divided into high dose group (75 cases) and low dose group (75 cases). The high dose group and the low dose group were given respectively with the 6 mg daily dose and the 3 mg daily dose of budesonide aerosol inhalation. The changes of the CAT scores, lung function, blood gas indicators, total treatment effective rates and adverse reaction rate were compared between the two groups before and after treatment. Results After treatment, the CAT score of the high dose group (8.09) was lower than that of the low dose group (9.71), there was significant difference(P<0.05) between them; the lung function indexes FEV1, FEV1/FVC and FEV1% predicted of the high dose group (1.80 L, 66.32% and 62.77) were respectively higher than those of the low dose group (1.64 L, 58.43% and 57.99),and there were significant differences (P<0.05) between them; the blood gas index PO2 of the high dose group (82.45 mm Hg) was higher than that of the low dose group (73.62 mm Hg), and the PCO2 of the high dose group (58.03 mm Hg) was lower than that of the low dose group (63.95 mm Hg), there were significant differences (P<0.05) between them; the total effective rate of the high dose group (96.00%) was higher than that of the low dose group (81.33%),and there was significant difference (P<0.05) between them; there was no significant difference (P>0.05) between the adverse reaction rate of the high dose group (30.67%) and that of the low dose group (28.00%). Conclusion High dose of budesonide atomized inhalation suspension can effectively improve lung function and hypoxia in AECOPD patients, which has significant clinical effects,while the increase of adverse reaction rate is not obvious.

参考文献/References:

[1] 戴思平,李芳华.无创呼吸机在已经出现呼吸肌疲劳但不伴有呼吸衰竭的AECOPD患者中的应用价值[J].临床与病理杂志,2016,36(8): 1156-1161.
[2] Vogelmeier C F,Criner G J,Martinez F J,et al.Global strategy for the diagnosis,management and prevention of chronic obstructive lung disease 2017 report GOLD executive summary [J].Am J Respir Crit Care Med,2017,195 (5): 557-582.
[3] 慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组.慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017年更新版)[J].国际呼吸杂志,2017,37(14): 1041-1057.
[4] 呼吸系统疾病基层诊疗指南编写专家组.慢性阻塞性肺疾病基层诊治指南(2018)[J].中华全科医师杂志,2018,17(11): 856-870.
[5] Qian W,Huang G Z.Neutrophil CD64 as a marker of bacterial infection in acute exacerbations of chronic obstructive pulmo-nary disease [J].Immunol Invest,2016,45:490-503.
[6] 阮伟良,陈胜海.雾化吸入较大剂量布地奈德治疗COPD急性加重期的临床观察[J].浙江医学,2016,38(12): 1026-1027.
[7] 王海平,温娟莹.糖皮质激素类药物在呼吸内科中的用药现状及合理性评价[J].中国现代药物应用,2017,11(10): 136-137.
[8] 陈亚红.2017年GOLD慢性阻塞性肺疾病诊断、治疗及预防的全球策略解读[J].中国医学前沿杂志(电子版),2017,9(1): 37-47.
[9] Ucar E Y,Araz O,Meral M,et al.Two different dosages of nebulized steroid versus parenteral steroid in the management of COPD exacerbations: A randomized control trial[J].Med Sci Monit,2014,20: 513-520.
[10] Gunen H,Hacievliyagil S S,Yetkin O,et al.The role of nebulised budesonide in the treatment of exacerbations of COPD[J].Eur Respir J,2007,29(4): 660-667.
[11] Maltais F,Ostinelli J,Bourbeau J,et al.Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial[J].Am J Respir Crit Care Med,2002,165(5): 698-703.
[12] 杨争光,王鹏军.不同剂量布地奈德混悬液对COPD患者疗效、激素抵抗性及安全性的影响[J].临床医学研究与实践,2019,4(17):13-15.
[13] 张蕊,陈碧,李元芹,等.雾化吸入不同剂量布地奈德在治疗慢性阻塞性肺病急性加重期的疗效[J].实用医学杂志,2019,35(24): 3827-3831.
[14] 中华医学会临床药学分会《雾化吸入疗法合理用药专家共识》编写组.雾化吸入疗法合理用药专家共识(2019年版)[J].医药导报,2019,38(2): 135-146.
[15] 周雁苹,郑镇波,周鹤铭,等.AECOPD患者采用不同剂量布地奈德雾化吸入治疗的临床疗效[J].现代诊断与治疗,2019,30(9): 1521-1523.
[16] 戴凯丽,张薇,刘磊.吸入性糖皮质激素在慢性阻塞性肺疾病应用中的新进展[J].医学综述,2016,22(23): 4645-4648.

相似文献/References:

[1]许能銮,郑建狮,陈愉生,等.慢性阻塞性肺疾病急性加重期205例出院后1年内死亡的相关因素分析[J].福建医药杂志,2022,44(01):18.
 XU Nengluan,ZHENG Jianshi,CHEN Yusheng,et al.Analysis of factors related to the death within one year after discharge in 205 patients with acute exacerbation of chronic obstructive pulmonary disease[J].FUJIAN MEDICAL JOURNAL,2022,44(02):18.

更新日期/Last Update: 2023-04-15